CTLA-4 Antigen

"CTLA-4 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.

Descriptor ID	D060908
MeSH Number(s)	D12.776.543.750.705.222.750 D23.050.301.264.894.158 D23.101.100.894.158
Concept/Terms	CTLA-4 Antigen CTLA-4 Antigen Antigen, CTLA-4 CTLA 4 Antigen Antigens, CD152 CD152 Antigens Cytotoxic T-Lymphocyte-Associated Antigen 4 Cytotoxic T Lymphocyte Associated Antigen 4 Cytotoxic T-Lymphocyte Antigen 4 Cytotoxic T Lymphocyte Antigen 4 CD152 Antigen Antigen, CD152

Below are MeSH descriptors whose meaning is more general than "CTLA-4 Antigen".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, Immunologic [D12.776.543.750.705]
Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
CTLA-4 Antigen [D12.776.543.750.705.222.750]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Antigens, Differentiation [D23.050.301.264]
Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
CTLA-4 Antigen [D23.050.301.264.894.158]
Biomarkers [D23.101]
Antigens, Differentiation [D23.101.100]
Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
CTLA-4 Antigen [D23.101.100.894.158]

Below are MeSH descriptors whose meaning is more specific than "CTLA-4 Antigen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "CTLA-4 Antigen" by people in this website by year, and whether "CTLA-4 Antigen" was a major or minor topic of these publications.

Bar chart showing 10 publications over 10 distinct years, with a maximum of 1 publications in 2000 and 2008 and 2013 and 2014 and 2015 and 2016 and 2017 and 2018 and 2020 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2008	0	1	1
2013	1	0	1
2014	0	1	1
2015	0	1	1
2016	1	0	1
2017	0	1	1
2018	0	1	1
2020	0	1	1
2024	0	1	1

Below are the most recent publications written about "CTLA-4 Antigen" by people in Profiles.

Knorr DA, Blanchard L, Leidner RS, Jensen SM, Meng R, Jones A, Ballesteros-Merino C, Bell RB, Baez M, Marino A, Sprott D, Bifulco CB, Piening B, Dahan R, Osorio JC, Fox BA, Ravetch JV. Fc?RIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer Immunol Res. 2024 03 04; 12(3):322-333.

View in: PubMed
Ladomersky E, Zhai L, Lauing KL, Bell A, Xu J, Kocherginsky M, Zhang B, Wu JD, Podojil JR, Platanias LC, Mochizuki AY, Prins RM, Kumthekar P, Raizer JJ, Dixit K, Lukas RV, Horbinski C, Wei M, Zhou C, Pawelec G, Campisi J, Grohmann U, Prendergast GC, Munn DH, Wainwright DA. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 10 01; 26(19):5232-5245.

View in: PubMed
Knorr DA, Dahan R, Ravetch JV. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. Proc Natl Acad Sci U S A. 2018 10 23; 115(43):11048-11053.

View in: PubMed
Roviello G, Andre F, Venturini S, Pistilli B, Curigliano G, Cristofanilli M, Rosellini P, Generali D. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. Eur J Cancer. 2017 11; 86:257-265.

View in: PubMed
Shields CL, Say EA, Mashayekhi A, Garg SJ, Dunn JP, Shields JA. Assessment of CTLA-4 Deficiency-Related Autoimmune Choroidopathy Response to Abatacept. JAMA Ophthalmol. 2016 07 01; 134(7):844-6.

View in: PubMed
Reese Z, Straubhar A, Pal SK, Agarwal N. Ipilimumab in the treatment of prostate cancer. Future Oncol. 2015; 11(1):27-37.

View in: PubMed
Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014 Aug 28; 158(5):989-999.

View in: PubMed
Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013 Aug 26; 210(9):1695-710.

View in: PubMed
Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother. 2008 Jul-Aug; 31(6):569-76.

View in: PubMed
Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000 Oct 06; 290(5489):84-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement